Table 2.
Baseline characteristics of the 27 patients included in the study.
| Characteristics | All = 27 |
|---|---|
| Age, mean years, (SD) | 67.2 (8.5) |
| Sex (men), number (%) | 14 (51.9) |
| Number of taxanes (nab-paclitaxel/paclitaxel/docetaxel) | 13/8/6 |
| Bilateral (%) | 23 (85.2) |
| Number of days from the initial taxane therapy to the ophthalmology visit, days (SD) | 290.1 (267.4) |
| BCVA at the initial visit, OD/OS, mean logMAR units (SD) | 0.28 (0.23)/0.41 (0.29) |
| CMT, OD/OS, mean (SD) μm | 422.8 (108.6)/464.4 (144.6) |
| CCT, OD/OS, mean (SD) μm | 282.1 (71.8)/288.2 (81.6) |
SD standard deviation, BCVA best-corrected visual acuity, CMT central macular thickness, CCT central choroidal thickness, OD oculus dexter, OS oculus sinister.